News Release

Warning on use of drug for children's sleep

Peer-Reviewed Publication

University of Adelaide

Sleep researchers at the University of Adelaide are warning doctors and parents not to provide the drug melatonin to children to help control their sleep problems.

Melatonin is a hormone produced in the body with the onset of darkness. It plays an important role in fine tuning people's circadian rhythms, such as the timing of sleep onset, as well as other biological processes.

In a paper published in the Journal of Paediatrics and Child Health, Professor David Kennaway, Head of the Circadian Physiology Laboratory at the University of Adelaide's Robinson Research Institute, warns that providing melatonin supplements to children may result in serious side effects when the children are older.

"The use of melatonin as a drug for the treatment of sleep disorders for children is increasing and this is rather alarming," Professor Kennaway says.

Professor Kennaway says the United States is the only country where melatonin is completely unregulated. "It's considered to be a 'dietary supplement', not a regulated drug, and is therefore readily available," he says.

"In Australia, melatonin is registered as a treatment for primary insomnia only for people aged 55 years and over, but it's easily prescribed as an 'off label' treatment for sleep disorders for children."

Professor Kennaway says there is extensive evidence from laboratory studies that melatonin causes changes in multiple physiological systems, including cardiovascular, immune and metabolic systems, as well as reproduction in animals.

"Melatonin is also a registered veterinary drug which is used for changing the seasonal patterns of sheep and goats, so they are more productive for industry. If doctors told parents that information before prescribing the drug to their children, I'm sure most would think twice about giving it to their child," Professor Kennaway says.

"The word 'safe' is used very freely and loosely with this drug, but there have been no rigorous, long-term safety studies of the use of melatonin to treat sleep disorders in children and adolescents.

"There is also the potential for melatonin to interact with other drugs commonly prescribed for children, but it's difficult to know without clinical trials assessing its safety."

Professor Kennaway, who has been researching melatonin for the past 40 years, says these concerns have largely been ignored throughout the world.

"Considering the small advances melatonin provides to the timing of sleep, and considering what we know about how melatonin works in the body, it is not worth the risk to child and adolescent safety," he says.

###

Media Contact:

Professor David Kennaway
Head, Circadian Physiology Laboratory
Robinson Research Institute
The University of Adelaide
Phone: +61 8 8313 4090
david.kennaway@adelaide.edu.au


Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.